Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Abbott Laboratories (ABT) is back in focus after presenting new multi-biomarker data for its Cancerguard multi cancer early ...

Is ABT a good stock to buy? We came across a bullish thesis on Abbott Laboratories on Compounding Dividends’s Substack by TJ Terwilliger. In this article, we will summarize the bulls’ thesis on ABT.

Abbott Laboratories (NYSE: ABT) more or less met analyst estimates in its first quarter, the results of which were published ...

Abbott Laboratories stock has been punished hard in 2026, and the question is whether that punishment has overshot the ...

They offer investors very different value propositions.

Abbott Laboratories' business, if not exciting, is resilient and consistent. The company is a leader in multiple markets and has attractive growth avenues. The medical device leader boasts a strong ...

Abbott Laboratories (NYSE:ABT) is preparing to release its quarterly earnings on Thursday, 2026-01-22. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

Buy the dip on Abbott (ABT): diversified healthcare growth, Exact Sciences boost, strong dividend, and discounted ...

If you are wondering whether Abbott Laboratories at around US$100 a share still reflects its underlying worth, you are not ...